These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 8425206)

  • 1. Adhesion of metastatic, ras-transformed NIH 3T3 cells to osteopontin, fibronectin, and laminin.
    Chambers AF; Hota C; Prince CW
    Cancer Res; 1993 Feb; 53(3):701-6. PubMed ID: 8425206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions.
    Xuan JW; Hota C; Shigeyama Y; D'Errico JA; Somerman MJ; Chambers AF
    J Cell Biochem; 1995 Apr; 57(4):680-90. PubMed ID: 7542253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA.
    Behrend EI; Craig AM; Wilson SM; Denhardt DT; Chambers AF
    Cancer Res; 1994 Feb; 54(3):832-7. PubMed ID: 8306346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells.
    Chambers AF; Behrend EI; Wilson SM; Denhardt DT
    Anticancer Res; 1992; 12(1):43-7. PubMed ID: 1567180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion.
    Xuan JW; Hota C; Chambers AF
    J Cell Biochem; 1994 Feb; 54(2):247-55. PubMed ID: 8175899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene.
    Wu Y; Denhardt DT; Rittling SR
    Br J Cancer; 2000 Jul; 83(2):156-63. PubMed ID: 10901364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells.
    Shanmugam V; Chackalaparampil I; Kundu GC; Mukherjee AB; Mukherjee BB
    Biochemistry; 1997 May; 36(19):5729-38. PubMed ID: 9153413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin.
    Bautista DS; Xuan JW; Hota C; Chambers AF; Harris JF
    J Biol Chem; 1994 Sep; 269(37):23280-5. PubMed ID: 8083234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.
    Teramoto H; Castellone MD; Malek RL; Letwin N; Frank B; Gutkind JS; Lee NH
    Oncogene; 2005 Jan; 24(3):489-501. PubMed ID: 15516973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming JB6 cells exhibit enhanced integrin-mediated adhesion to osteopontin.
    Chang PL; Chambers AF
    J Cell Biochem; 2000 Apr; 78(1):8-23. PubMed ID: 10797562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-RGD domains of osteopontin promote cell adhesion without involving alpha v integrins.
    Katagiri YU; Murakami M; Mori K; Iizuka J; Hara T; Tanaka K; Jia WY; Chambers AF; Uede T
    J Cell Biochem; 1996 Jul; 62(1):123-31. PubMed ID: 8836881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain.
    Senger DR; Perruzzi CA; Papadopoulos-Sergiou A; Van de Water L
    Mol Biol Cell; 1994 May; 5(5):565-74. PubMed ID: 7522656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation and function of osteopontin in ras-transformed cells.
    Chambers AF
    Ann N Y Acad Sci; 1995 Apr; 760():101-8. PubMed ID: 7785889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cell-substrate adhesion accompanies conditional reversion to the normal phenotype in ras-oncogene-transformed NIH-3T3 cells.
    Shumaker DK; Sklar MD; Prochownik EV; Varani J
    Exp Cell Res; 1994 Oct; 214(2):440-6. PubMed ID: 7925639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
    Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF
    Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts.
    Gardner HA; Berse B; Senger DR
    Oncogene; 1994 Aug; 9(8):2321-6. PubMed ID: 8036014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer.
    Zhu Y; Denhardt DT; Cao H; Sutphin PD; Koong AC; Giaccia AJ; Le QT
    Oncogene; 2005 Sep; 24(43):6555-63. PubMed ID: 16007184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter.
    Denhardt DT; Mistretta D; Chambers AF; Krishna S; Porter JF; Raghuram S; Rittling SR
    Clin Exp Metastasis; 2003; 20(1):77-84. PubMed ID: 12650610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ras-responsive genes and tumor metastasis.
    Chambers AF; Tuck AB
    Crit Rev Oncog; 1993; 4(2):95-114. PubMed ID: 8420573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-derived osteopontin is soluble, not matrix associated.
    Rittling SR; Chen Y; Feng F; Wu Y
    J Biol Chem; 2002 Mar; 277(11):9175-82. PubMed ID: 11741994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.